SBIR/STTR Research Award
LATE STAGE ADJUVANT MIMICS BASED ON TLR4 AGONISTS
Award amount
$597,953Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PAI LIFE SCIENCES INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- MSMLUCM9DRT6
- Solicitation number
- PHS-2021-1
- Topic code
- 93
Research abstract
The proprietary combination adjuvants AS01 and AS04 are used in approved vaccines (Shingrix and Cervarix, respectively). Another successful adjuvant, GLA-SE, is currently in late-stage clinical trials. To make these classes of adjuvants available to vaccine developers, the contractor is developing functional mimics for low-cost and effective vaccines against emerging diseases and to address major health gaps worldwide.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield
- A Vaccine for Lymphatic Filariasis, LFGuard™
- Evaluation of a Next Generation SchistoShield Vaccine
- Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
- A Vaccine for Schistosomiasis, "SchistoShield"
Research funding history
28 SBIR/STTR records share this UEI (2007–2024). Reported award amounts total $23,806,620. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services